Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls

European Journal of Endocrinology

Volumn 163, Issue 5, 2010, Pages 833-837

  Van Lierop, A H ^a   Witteveen, J E ^a   Hamdy, N A T ^a   Papapoulos, S E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CREATININE; PARATHYROID HORMONE; PHOSPHATE; SCLEROSTIN; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, HUMAN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DOWN REGULATION; FEMALE; HUMAN; MALE; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; VITAMIN BLOOD LEVEL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; BONE REMODELING; COMPARATIVE STUDY; GENETIC MARKER; HYPERPARATHYROIDISM, PRIMARY; MIDDLE AGED; PARATHYROID GLAND; PHYSIOLOGY; SECRETION (PROCESS);

ADULT; AGED; BIOLOGICAL MARKERS; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; DOWN-REGULATION; FEMALE; GENETIC MARKERS; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MALE; MIDDLE AGED; PARATHYROID GLANDS; PARATHYROID HORMONE;

EID: 77957838571     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0699     Document Type: Article

References (24)

1. Mosekilde L. Primary hyperparathyroidism and the skeleton. Clinical Endocrinology 2008 69 1-19. (doi:10.1111/j.1365-2265.2007.03162.x)
2. Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD & Nissenson RA. PTH differentially regulates expression of RANKL and OPG. Journal of Bone and Mineral Research 2004 19 235-244. (doi:10.1359/JBMR.0301226) (Pubitemid 38116737)
3. Lee SK & Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999 140 3552-3561. (doi:10.1210/en.140.8.3552)
4. Locklin RM, Khosla S, Turner RT & Riggs BL. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. Journal of Cellular Biochemistry 2003 89 180-190. (doi:10.1002/jcb. 10490) (Pubitemid 36459108)
5. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ & Onyia JE. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2001 142 4047-4054. (doi:10.1210/en.142.9.4047)
6. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC & Jilka RL. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005 146 4577-4583. (doi:10.1210/en.2005- 0239)
7. Keller H & Kneissel M. SOST is a target gene for PTH in bone. Bone 2005 37 148-158. (doi:10.1016/j.bone.2005.03.018) (Pubitemid 40962421)
8. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC & Bellido T. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE 2008 3 e2942. (doi:10.1371/journal.pone. 0002942)
9. Silvestrini G, Ballanti P, Leopizzi M, Sebastiani M, Berni S, Di Vito M & Bonucci E. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. Journal of Molecular Histology 2007 38 261-269. (doi:10.1007/s10735-007-9096-3)
10. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P & Löwik CW. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. Journal of Experimental Medicine 2004 199 805-814. (doi:10.1084/jem.20031454)
11. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE & Wu D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. Journal of Biological Chemistry 2005 280 19883-19887. (doi:10.1074/jbc.M413274200)
12. Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S & Krumlauf R. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. Journal of Bone and Mineral Research 2006 21 1738-1749. (doi:10.1359/jbmr.060810)
13. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D & Van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Human Molecular Genetics 2001 10 537-543. (doi:10.1093/hmg/10.5.537)
14. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D 'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ & Paszty C. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. Journal of Bone and Mineral Research 2008 23 860-869. (doi:10.1359/jbmr.080216) (Pubitemid 351768804)
15. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, Lightwood DJ, Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS & Paszty C. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. Journal of Bone and Mineral Research 2010 25 948-959. (doi:10.1002/jbmr.14)
16. Padhi D, Stouch B, Jang G, Fang L, Darling M, Glise H, Robinson M, Harris S & Posvar E. Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women. Journal of Bone and Mineral Research 2007 22 S37.
17. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Karen Staehling-Hampton KS, Appleby M, Brunkow ME & Latham JA. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO Journal 2003 22 6267-6276. (doi:10.1093/emboj/ cdg599) (Pubitemid 37522584)
18. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE & Turner CH. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. Journal of Biological Chemistry 2008 283 5866-5875. (doi:10.1074/jbc.M705092200)
19. Kramer I, Loots GG, Studer A, Keller H & Kneissel M. Parathyroid hormone (PTH) induced bone gain is blunted in SOST overexpressing and deficient mice. Journal of Bone and Mineral Research 2010 25 178-189. (doi:10.1359/jbmr. 090730)
20. Mirza FS, Padhi ID, Raisz LG & Lorenzo JA. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 2010 95 1991-1997. (doi:10.1210/jc.2009-2283)
21. Drake MT, Srinivasan B, Modder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P & Khosla S. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 2010. (doi:10.1210/jc.2010-0720)
22. Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Lawrence RB, Joseph ML & Khosla S. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. Journal of Bone and Mineral Research, 2010. (doi:10.1002/jbmr.217)
23. Datta NS & Abou-Samra AB. PTH and PTHrP signaling in osteoblasts. Cellular Signalling 2009 21 1245-1254. (doi:10.1016/j.cellsig.2009.02.012)
24. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007 40 1434-1446. (doi:10.1016/j.bone.2007.03.017)